The proteins associated with these neuroprotective effects (HTT, NEFH and NEFL) are potential drug targets for the treatment of obesity-induced cognitive impairment with semaglutide. The gene discussed is NEFL; the disease is obesity due to melanocortin 4 receptor deficiency.